{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["32(4)"],"submitter":["Montero-Hidalgo AJ"],"pubmed_abstract":["Prostate cancer (PCa) is the second most common cancer among men worldwide. The main screening tool remains the prostate-specific antigen (PSA), which shows significant limitations, including poor sensitivity/specificity. Therefore, establishing accurate non-invasive diagnostic biomarkers remains an unmet clinical need in PCa. In this context, the splicing process dysregulation represents a PCa hallmark. Here, plasma SRRM1, SNRNP200, and SRSF3 levels, previously identified to play a pathophysiological role in PCa, were determined in control individuals (<i>n</i> = 40) and PCa patients (<i>n</i> = 166). We found that plasma SRRM1 and SNRNP200 levels were elevated in PCa patients and discriminated between control individuals and PCa patients. High plasma SRRM1 levels were associated with a shorter castration-resistant PCa-free survival and correlated with androgen-receptor (AR)/AR-splicing variant 7 (AR-V7) expression levels and activity in PCa tissues. Therefore, the functional and molecular effects of <i>in vivo</i> SRRM1 silencing were then tested in 22Rv1-derived xenograft tumors. <i>In vivo</i> SRRM1 silencing reduced aggressiveness features and altered AR/AR-V7 activity. Our data reveal that SRRM1 holds potential as a non-invasive diagnostic and prognostic biomarker and novel therapeutic target in PCa, offering a clinically relevant opportunity worth exploring in humans."],"journal":["Molecular therapy. Oncology"],"pagination":["200910"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11697196"],"repository":["biostudies-literature"],"pubmed_title":["Clinical value of circulating splicing factors in prostate cancer: SRRM1 as a novel predictive biomarker and therapeutic target."],"pmcid":["PMC11697196"],"pubmed_authors":["Rangel-Zuniga OA","Porcel-Pastrana F","Luque RM","Sarmento-Cabral A","Jimenez-Vacas JM","Perez-Gomez JM","Montero-Hidalgo AJ","Gonzalez-Serrano T","Ortega-Bellido M","Chamorro-Castillo L","Gahete MD","Gomez-Gomez E","Campos-Hernandez JP","Carrasco-Valiente J","Galan-Canete M","Sanchez-Sanchez R"],"additional_accession":[]},"is_claimable":false,"name":"Clinical value of circulating splicing factors in prostate cancer: SRRM1 as a novel predictive biomarker and therapeutic target.","description":"Prostate cancer (PCa) is the second most common cancer among men worldwide. The main screening tool remains the prostate-specific antigen (PSA), which shows significant limitations, including poor sensitivity/specificity. Therefore, establishing accurate non-invasive diagnostic biomarkers remains an unmet clinical need in PCa. In this context, the splicing process dysregulation represents a PCa hallmark. Here, plasma SRRM1, SNRNP200, and SRSF3 levels, previously identified to play a pathophysiological role in PCa, were determined in control individuals (<i>n</i> = 40) and PCa patients (<i>n</i> = 166). We found that plasma SRRM1 and SNRNP200 levels were elevated in PCa patients and discriminated between control individuals and PCa patients. High plasma SRRM1 levels were associated with a shorter castration-resistant PCa-free survival and correlated with androgen-receptor (AR)/AR-splicing variant 7 (AR-V7) expression levels and activity in PCa tissues. Therefore, the functional and molecular effects of <i>in vivo</i> SRRM1 silencing were then tested in 22Rv1-derived xenograft tumors. <i>In vivo</i> SRRM1 silencing reduced aggressiveness features and altered AR/AR-V7 activity. Our data reveal that SRRM1 holds potential as a non-invasive diagnostic and prognostic biomarker and novel therapeutic target in PCa, offering a clinically relevant opportunity worth exploring in humans.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2026-06-02T08:00:53.586Z","creation":"2026-04-16T03:10:18.492Z"},"accession":"S-EPMC11697196","cross_references":{"pubmed":["39758250"],"doi":["10.1016/j.omton.2024.200910"]}}